Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Strategic Planning for Life Science Companies: Key Considerations

Mar 23, 2025

Introduction to Strategic Planning in Life Sciences

Strategic planning is a crucial aspect for life science companies aiming to drive innovation and stay competitive in a rapidly evolving industry. It involves setting clear objectives, identifying growth opportunities, and anticipating challenges. For companies in the life sciences sector, strategic planning not only facilitates operational efficiency but also aligns their products and services with the changing landscape of healthcare needs.

Understanding the unique challenges and opportunities within the life science industry is essential for effective strategic planning. From emerging technologies to regulatory changes, companies need to be agile and forward-thinking to succeed. In this blog post, we explore key considerations that life science companies should keep in mind when developing their strategic plans.

life sciences strategy

Understanding Market Trends and Innovations

The life sciences industry is characterized by continuous advancements and breakthroughs. Therefore, keeping abreast of market trends and technological innovations is vital. Companies should invest in market research to understand current demands and forecast future trends. This information can help in tailoring products and services to meet evolving needs.

Key innovations such as personalized medicine, digital health solutions, and biotechnological advancements are reshaping the industry landscape. Strategic planning should incorporate these advancements to ensure that the company remains at the forefront of innovation.

The Role of Data Analytics

Data analytics plays an increasingly important role in strategic planning for life science companies. By leveraging data, companies can gain insights into customer behavior, market trends, and operational efficiency. This information can guide decision-making processes and help identify areas for improvement.

data analytics life sciences

Regulatory Compliance and Risk Management

Regulatory compliance is a significant consideration for life science companies. Navigating the complex regulatory landscape requires a thorough understanding of both local and international regulations. Strategic planning should include a comprehensive compliance strategy to avoid potential legal issues and ensure smooth operations.

Additionally, risk management is an integral part of strategic planning. Companies should identify potential risks, such as supply chain disruptions or changes in regulatory policies, and develop contingency plans to mitigate these risks effectively.

Emphasizing Sustainability

Sustainability is becoming increasingly important in the life sciences industry. Companies are expected to adopt sustainable practices not only to meet regulatory requirements but also to align with consumer expectations. Strategic planning should incorporate sustainability initiatives, such as reducing waste and minimizing environmental impact.

sustainability life sciences

Collaboration and Partnerships

Collaboration is a key driver of innovation in the life sciences sector. Strategic partnerships with research institutions, technology providers, and other industry players can open up new avenues for growth and development. These collaborations can help companies access new technologies, share resources, and tap into new markets.

Building strong networks and partnerships can also enhance a company's reputation and credibility within the industry. It's important for companies to identify potential partners who share their vision and values for effective collaboration.

Conclusion: The Future of Strategic Planning

The future of strategic planning in the life sciences industry will be shaped by ongoing technological advancements, evolving regulations, and changing consumer expectations. Companies must remain adaptable and proactive in their approach to strategic planning to ensure sustained growth and success.

By considering market trends, leveraging data analytics, ensuring regulatory compliance, emphasizing sustainability, and fostering collaborations, life science companies can develop robust strategic plans that position them for long-term success.